Next Gen Interactive Plaque Analysis Platform Assesses Patient Risk in Suspected Coronary Artery Disease

A first-of-its-kind plaque analysis tool to be fully integrated with FFRCT (when FFRCT is performed) provides impactful insights that enhance clinical decision-making and enable personalized patient treatment strategies.

HeartFlow, Inc. (Mountain View, CA, USA) has launched the next-generation HeartFlow Plaque Analysis with an interactive experience. This upgraded platform employs advanced proprietary algorithms to analyze coronary CT angiogram (CCTA) scans, generating a personalized 3D model that quantifies and characterizes plaque within the coronary arteries, thus aiding in the risk assessment of coronary artery disease. When combined with FFRCT analysis, this interactive tool enriches the diagnostic experience by integrating highly accurate plaque quantification with lesion-specific FFRCT values, displaying a detailed 3D plaque model and extensive plaque analysis by territory across calcified, non-calcified, and low attenuation categories.

Additionally, the platform enables clinicians to view color-coded cross-sectional images of each plaque type as quantified along the vessel, providing a comprehensive overview of a patient's plaque burden to inform personalized treatment approaches. The effectiveness of the HeartFlow Plaque Analysis was demonstrated in the REVEALPLAQUE study which showed that HeartFlow Plaque Analysis is the only non-invasive plaque assessment with 95% agreement for total plaque volume measures when compared to the gold standard IVUS. Moreover, the study revealed that medical management was changed and more precisely tailored for two-thirds of the patients based on insights gained from the HeartFlow Plaque Analysis.

“Accurately diagnosing a patient’s risk for coronary artery disease is critical for determining the best treatment. Our new interactive plaque experience marks an exciting era in AI-enabled cardiac technology, where we are now the only company that offers a fully integrated view of a patient’s true burden of coronary artery disease,” said HeartFlow chief medical officer Campbell Rogers, M.D., F.A.C.C. “The elevated visualization of Plaque Analysis integrated with our flagship FFRCT Analysis, sets HeartFlow apart as a wholistic solution for CT analysis, enabling physicians to enhance personalized treatment decisions.”

Related Links:
HeartFlow, Inc.

Visit expo >

Mobile Barrier

Tilted Mobile Leaded Barrier

New

X-Ray Illuminator

X-Ray Viewbox Illuminators

New

Portable HF X-Ray Machine

PORTX

New

Ultrasound Probe Disinfection Solution

UltrOx